product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Mouse TRANCE/RANK L/TNFSF11 (E. coli), CF
catalog :
462-TEC-010/CF
quantity :
10 ug
price :
394 USD
more info or order :
citations: 73
Reference
Zhang Y, Yang M, Zhang S, Yang Z, Zhu Y, Wang Y, et al. BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1. Cell Biosci. 2022;12:70 pubmed publisher
Cai P, Yan S, Lu Y, Zhou X, Wang X, Wang M, et al. Carnosol inhibits osteoclastogenesis in vivo and in vitro by blocking the RANKL‑induced NF‑κB signaling pathway. Mol Med Rep. 2022;26: pubmed publisher
Cui Z, Feng C, Chen J, Wang Y, Meng Q, Zhao S, et al. Network Pharmacology Deciphers the Action of Bioactive Polypeptide in Attenuating Inflammatory Osteolysis via the Suppression of Oxidative Stress and Restoration of Bone Remodeling Balance. Oxid Med Cell Longev. 2022;2022:4913534 pubmed publisher
Ma Y, DI R, Zhao H, Song R, Zou H, Liu Z. P2X7 receptor knockdown suppresses osteoclast differentiation by inhibiting autophagy and Ca2+/calcineurin signaling. Mol Med Rep. 2022;25: pubmed publisher
Yang C, Tao H, Zhang H, Xia Y, Bai J, Ge G, et al. TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss. Autophagy. 2022;:1-13 pubmed publisher
Kim J, Yang Y, Xie J, Lee O, Kim J, Hong J, et al. Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes. Cell Death Differ. 2022;: pubmed publisher
Mamun Or Rashid A, Lucy T, Yagi M, Yonei Y. Inhibitory Effects of Astaxanthin on CML-HSA-Induced Inflammatory and RANKL-Induced Osteoclastogenic Gene Expression in RAW 264.7 Cells. Biomedicines. 2021;10: pubmed publisher
Gu J, Zhang X, Zhang C, Li Y, Bian J, Liu X, et al. Galectin-3 Contributes to the Inhibitory Effect of lα,25-(OH)2D3 on Osteoclastogenesis. Int J Mol Sci. 2021;22: pubmed publisher
Zhou S, Dai Q, Huang X, Jin A, Yang Y, Gong X, et al. STAT3 is critical for skeletal development and bone homeostasis by regulating osteogenesis. Nat Commun. 2021;12:6891 pubmed publisher
Zhang Y, Zhang S, Wang Y, Yang Z, Chen Z, Wen N, et al. ULK1 Suppresses Osteoclast Differentiation and Bone Resorption via Inhibiting Syk-JNK through DOK3. Oxid Med Cell Longev. 2021;2021:2896674 pubmed publisher
Liu Z, Wang H, Hou Y, Yang Y, Jia J, Wu J, et al. CNC-bZIP protein NFE2L1 regulates osteoclast differentiation in antioxidant-dependent and independent manners. Redox Biol. 2021;48:102180 pubmed publisher
Nilsson K, Henning P, El Shahawy M, Nethander M, Andersen T, Ejersted C, et al. RSPO3 is important for trabecular bone and fracture risk in mice and humans. Nat Commun. 2021;12:4923 pubmed publisher
Fang C, Guo J, Wang Y, Li X, Zhang H, Cui J, et al. Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion. Acta Pharmacol Sin. 2021;: pubmed publisher
Wang K, Donnelly C, Jiang C, Liao Y, Luo X, Tao X, et al. STING suppresses bone cancer pain via immune and neuronal modulation. Nat Commun. 2021;12:4558 pubmed publisher
Chen H, Shen G, Shang Q, Zhang P, Yu D, Yu X, et al. Plastrum testudinis extract suppresses osteoclast differentiation via the NF-κB signaling pathway and ameliorates senile osteoporosis. J Ethnopharmacol. 2021;276:114195 pubmed publisher
Xue P, Hu X, Chang E, Wang L, Chen M, Wu T, et al. Deficiency of optineurin enhances osteoclast differentiation by attenuating the NRF2-mediated antioxidant response. Exp Mol Med. 2021;53:667-680 pubmed publisher
Wei H, Xu Y, Wang Y, Xu L, Mo C, Li L, et al. Identification of Fibroblast Activation Protein as an Osteogenic Suppressor and Anti-osteoporosis Drug Target. Cell Rep. 2020;33:108252 pubmed publisher
Chen Y, Wang Y, Tang R, Yang J, Dou C, Dong Y, et al. Dendritic cells-derived interferon-λ1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesis. Cell Death Dis. 2020;11:414 pubmed publisher
Wang K, Gu Y, Liao Y, Bang S, Donnelly C, Chen O, et al. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. J Clin Invest. 2020;130:3603-3620 pubmed publisher
Kim J, Yang Y, Park K, Ge X, Xu R, Li N, et al. A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nat Commun. 2020;11:2289 pubmed publisher
Du T, Yan Z, Zhu S, Chen G, Wang L, Ye Z, et al. QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism. Cell Death Dis. 2020;11:330 pubmed publisher
Kim S, Jeong Y, Jeong S, Park M, Go H, Kim M, et al. Neural regulation of energy and bone homeostasis by the synaptic adhesion molecule Calsyntenin-3. Exp Mol Med. 2020;52:793-803 pubmed publisher
Kang I, Jang J, Kim C. Opposing roles of hematopoietic-specific small GTPase Rac2 and the guanine nucleotide exchange factor Vav1 in osteoclast differentiation. Sci Rep. 2020;10:7024 pubmed publisher
Lei W, Duan R, Li J, Liu X, Huston A, Boyce B, et al. The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice. Sci Rep. 2020;10:7004 pubmed publisher
Kiyohara S, Sakai N, Handa K, Yamakawa T, Ishikawa K, Chatani M, et al. Effects of N-methyl-d-aspartate receptor antagonist MK-801 (dizocilpine) on bone homeostasis in mice. J Oral Biosci. 2020;62:131-138 pubmed publisher
Zhang Y, Yang K, Yang J, Lao Y, Deng L, Deng G, et al. SENP3 Suppresses Osteoclastogenesis by De-conjugating SUMO2/3 from IRF8 in Bone Marrow-Derived Monocytes. Cell Rep. 2020;30:1951-1963.e4 pubmed publisher
Brunner J, Vulliard L, Hofmann M, Kieler M, Lercher A, Vogel A, et al. Environmental arginine controls multinuclear giant cell metabolism and formation. Nat Commun. 2020;11:431 pubmed publisher
Pore S, Hahm E, Kim S, Singh K, Nyiranshuti L, Latoche J, et al. A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption. Mol Cancer Ther. 2020;19:420-431 pubmed publisher
Shang N, Wu J. Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption. Nutrients. 2019;11: pubmed publisher
Li L, Ameri A, Wang S, Jansson K, Casey O, Yang Q, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 2019;38:6241-6255 pubmed publisher
Wong S, Huang B, Hu X, Ho Kim E, Kolb J, Padilla R, et al. Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease. Cell Death Differ. 2019;: pubmed publisher
Bergsma A, Ganguly S, Wiegand M, Dick D, Williams B, Miranti C. Regulation of cytoskeleton and adhesion signaling in osteoclasts by tetraspanin CD82. Bone Rep. 2019;10:100196 pubmed publisher
Muschter D, Beiderbeck A, Späth T, Kirschneck C, Schröder A, Grassel S. Sensory Neuropeptides and their Receptors Participate in Mechano-Regulation of Murine Macrophages. Int J Mol Sci. 2019;20: pubmed publisher
Jones J, Sinder B, Paige D, Soki F, Koh A, Thiele S, et al. Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis. Neoplasia. 2019;21:172-184 pubmed publisher
Wee N, Sinder B, Novak S, Wang X, Stoddard C, Matthews B, et al. Skeletal phenotype of the neuropeptide Y knockout mouse. Neuropeptides. 2019;73:78-88 pubmed publisher
Lee K, Park K, Hwang J, Lee M, Yoon D, Ryu H, et al. Inhibition of STAT5A promotes osteogenesis by DLX5 regulation. Cell Death Dis. 2018;9:1136 pubmed publisher
Wang H, Wang P, Chen Y, Zhang Y. Bevacizumab or fibronectin gene editing inhibits the osteoclastogenic effects of fibroblasts derived from human radicular cysts. Acta Pharmacol Sin. 2019;40:949-956 pubmed publisher
Mödinger Y, Rapp A, Pázmándi J, Vikman A, Holzmann K, Haffner Luntzer M, et al. C5aR1 interacts with TLR2 in osteoblasts and stimulates the osteoclast-inducing chemokine CXCL10. J Cell Mol Med. 2018;22:6002-6014 pubmed publisher
Ma G, Lee S, Park K, Park J, Son S, Jung M, et al. Artemisinin-Daumone Hybrid Inhibits Cancer Cell-Mediated Osteolysis by Targeting Cancer Cells and Osteoclasts. Cell Physiol Biochem. 2018;49:1460-1475 pubmed publisher
Ubellacker J, Baryawno N, Severe N, Decristo M, Sceneay J, Hutchinson J, et al. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Res. 2018;78:5300-5314 pubmed publisher
Niedermair T, Schirner S, Seebröker R, Straub R, Grassel S. Substance P modulates bone remodeling properties of murine osteoblasts and osteoclasts. Sci Rep. 2018;8:9199 pubmed publisher
Yu Z, Surface L, Park C, Horlbeck M, Wyant G, Abu Remaileh M, et al. Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. elife. 2018;7: pubmed publisher
Grcevic D, Sironi M, Valentino S, Deban L, Cvija H, Inforzato A, et al. The Long Pentraxin 3 Plays a Role in Bone Turnover and Repair. Front Immunol. 2018;9:417 pubmed publisher
Ishii T, Ruiz Torruella M, Ikeda A, Shindo S, Movila A, Mawardi H, et al. OC-STAMP promotes osteoclast fusion for pathogenic bone resorption in periodontitis via up-regulation of permissive fusogen CD9. FASEB J. 2018;32:4016-4030 pubmed publisher
Jia Z, Li H, Liang Y, Potempa L, Ji S, Wu Y. Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF-κB Ligand-Induced Osteoclast Differentiation. Front Immunol. 2018;9:234 pubmed publisher
Mediero A, Wilder T, Shah L, Cronstein B. Adenosine A2A receptor (A2AR) stimulation modulates expression of semaphorins 4D and 3A, regulators of bone homeostasis. FASEB J. 2018;32:3487-3501 pubmed publisher
Ye Q, Li G, Liu S, Guan Y, Li Y, Li J, et al. Targeted disruption of adenosine kinase in myeloid monocyte cells increases osteoclastogenesis and bone resorption in mice. Int J Mol Med. 2018;41:2177-2184 pubmed publisher
Kim C, Shin S, Kim B, Kim C, Kim J, Kang H, et al. The Effects of Kaempferol-Inhibited Autophagy on Osteoclast Formation. Int J Mol Sci. 2018;19: pubmed publisher
Quach D, Collins F, Parameswaran N, McCabe L, Britton R. Microbiota Reconstitution Does Not Cause Bone Loss in Germ-Free Mice. mSphere. 2018;3: pubmed publisher
Park H, Son Y, Lee S, Rho G, Kang Y, Park B, et al. Effects of Osteogenic-Conditioned Medium from Human Periosteum-Derived Cells on Osteoclast Differentiation. Int J Med Sci. 2017;14:1389-1401 pubmed publisher
Kram V, Kilts T, Bhattacharyya N, Li L, Young M. Small leucine rich proteoglycans, a novel link to osteoclastogenesis. Sci Rep. 2017;7:12627 pubmed publisher
Stattin E, Henning P, Klar J, McDermott E, Stecksen Blicks C, Sandström P, et al. SNX10 gene mutation leading to osteopetrosis with dysfunctional osteoclasts. Sci Rep. 2017;7:3012 pubmed publisher
Strålberg F, Kassem A, Kasprzykowski F, Abrahamson M, Grubb A, Lindholm C, et al. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors. J Leukoc Biol. 2017;101:1233-1243 pubmed publisher
Ramos Junior E, Leite G, Carmo Silva C, Taira T, Neves K, Colón D, et al. Adipokine Chemerin Bridges Metabolic Dyslipidemia and Alveolar Bone Loss in Mice. J Bone Miner Res. 2017;32:974-984 pubmed publisher
Batsir S, Geiger B, Kam Z. Dynamics of the sealing zone in cultured osteoclasts. Cytoskeleton (Hoboken). 2017;74:72-81 pubmed publisher
Karlsson T, Lundholm M, Widmark A, Persson E. Tumor Cell-Derived Exosomes from the Prostate Cancer Cell Line TRAMP-C1 Impair Osteoclast Formation and Differentiation. PLoS ONE. 2016;11:e0166284 pubmed publisher
Khor E, Fanshawe B, Qi Y, Zolotukhin S, Kulkarni R, Enriquez R, et al. Prader-Willi Critical Region, a Non-Translated, Imprinted Central Regulator of Bone Mass: Possible Role in Skeletal Abnormalities in Prader-Willi Syndrome. PLoS ONE. 2016;11:e0148155 pubmed publisher
Beier E, Sheu T, Dang D, Holz J, Ubayawardena R, Babij P, et al. Heavy Metal Ion Regulation of Gene Expression: MECHANISMS BY WHICH LEAD INHIBITS OSTEOBLASTIC BONE-FORMING ACTIVITY THROUGH MODULATION OF THE Wnt/β-CATENIN SIGNALING PATHWAY. J Biol Chem. 2015;290:18216-26 pubmed publisher
Fowler T, Kamalakar A, Akel N, Kurten R, Suva L, Gaddy D. Activin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures. J Cell Sci. 2015;128:683-94 pubmed publisher
Mediero A, Ramkhelawon B, Perez Aso M, Moore K, Cronstein B. Netrin-1 is a critical autocrine/paracrine factor for osteoclast differentiation. J Bone Miner Res. 2015;30:837-54 pubmed publisher
Nickel N, Godau J, Willie B, Duda G, Schwarzer R, Cirovic B, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J. 2014;4:e217 pubmed publisher
Zhang H, Hilton M, Anolik J, Welle S, Zhao C, Yao Z, et al. NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB. J Clin Invest. 2014;124:3200-14 pubmed publisher
Tiwari M, Sharma L, Vanegas D, Callaway D, Bai Y, Lechleiter J, et al. A nonapoptotic role for CASP2/caspase 2: modulation of autophagy. Autophagy. 2014;10:1054-70 pubmed publisher
Xiu Y, Xu H, Zhao C, Li J, Morita Y, Yao Z, et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Invest. 2014;124:297-310 pubmed publisher
Stalvey M, Clines K, Havasi V, McKibbin C, Dunn L, Chung W, et al. Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease. PLoS ONE. 2013;8:e80098 pubmed publisher
Sun Q, Sammut B, Wang F, Kurihara N, Windle J, Roodman G, et al. TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. J Bone Miner Res. 2014;29:90-102 pubmed publisher
Muruganandan S, Dranse H, Rourke J, McMullen N, Sinal C. Chemerin neutralization blocks hematopoietic stem cell osteoclastogenesis. Stem Cells. 2013;31:2172-82 pubmed publisher
Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, et al. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol. 2011;179:1157-70 pubmed publisher
Kulkarni R, Bakker A, Everts V, Klein Nulend J. Inhibition of osteoclastogenesis by mechanically loaded osteocytes: involvement of MEPE. Calcif Tissue Int. 2010;87:461-8 pubmed publisher
Binder N, Niederreiter B, Hoffmann O, Stange R, Pap T, Stulnig T, et al. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med. 2009;15:417-24 pubmed publisher
Johansson M, de Vries T, Schoenmaker T, Ehinger M, Brun A, Fasth A, et al. Hematopoietic stem cell-targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc/oc mice. Blood. 2007;109:5178-85 pubmed
de Vries T, Schoenmaker T, Wattanaroonwong N, van den Hoonaard M, Nieuwenhuijse A, Beertsen W, et al. Gingival fibroblasts are better at inhibiting osteoclast formation than periodontal ligament fibroblasts. J Cell Biochem. 2006;98:370-82 pubmed
Liao T, Yurgelun M, Chang S, Zhang H, Murakami K, Blaine T, et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res. 2005;23:203-9 pubmed
image
image 1 :
R&D Systems 462-TEC-010/CF image 1
Recombinant Mouse TRANCE/RANK L/TNFSF11 (E. coli) Bioactivity
product information
brand :
R&D Systems
master code :
462-TEC/CF
SKU :
462-TEC-010/CF
product name :
Recombinant Mouse TRANCE/RANK L/TNFSF11 (E. coli), CF
description :
The Recombinant Mouse TRANCE/RANK L/TNFSF11 (E. coli), CF from R&D Systems is derived from E. coli. The Recombinant Mouse TRANCE/RANK L/TNFSF11 (E. coli), CF has been validated for the following applications: Bioactivity.
target :
TRANCE/TNFSF11/RANK L
category :
Proteins and Enzymes
sizes available :
10 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in NaH2PO4, NaCl and EDTA.
conjugate :
Unconjugated
purity :
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
species :
Mouse
theoretical molecular weight :
19 kDa
gene symbol :
Tnfsf11
details of functionality :
Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 0.5-2 ng/mL.
endotoxin note :
<0.01 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
Q3TWY5
applications :
Bioactivity
source :
E. coli-derived Recombinant Mouse TRANCE/RANK L/TNFSF11 (E. coli), CF
USD :
388
USD 2023 :
394 USD
alt names :
CD254, CD254 antigen, ODF, OPGL, OPGLOPTB2, Osteoclast differentiation factor, Osteoprotegerin ligand, RANK L, RANKL, RANKLreceptor activator of nuclear factor kappa B ligand, Receptor activator of nuclear factor kappa-B ligand, sOdf, TNF-related activation-induced cytokine, TNFSF11, TRANCEODFhRANKL2, tumor necrosis factor (ligand) superfamily, member 11, tumor necrosis factor ligand superfamily member 11
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
more info or order :
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.